Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Druggable genome CRISPRi screen in hydrogels reveals regulators of cortactin-driven actin remodeling promoting glioblastoma invasion
Mufeng Hu, Anna Weldy, Isabella M. Lovalvo, Erin A. Akins, Saket Jain, Alexander Chang, Ankita Sati, Meeki Lad, Austin Lui, Akhil Rajidi, Ameya Kothekar, Erika A. Ding, Juan A. Oses Prieto, Pablo Estevez, Alma L. Burlingame, Sanjay Kumar, Manish K. Aghi
Mufeng Hu, Anna Weldy, Isabella M. Lovalvo, Erin A. Akins, Saket Jain, Alexander Chang, Ankita Sati, Meeki Lad, Austin Lui, Akhil Rajidi, Ameya Kothekar, Erika A. Ding, Juan A. Oses Prieto, Pablo Estevez, Alma L. Burlingame, Sanjay Kumar, Manish K. Aghi
View: Text | PDF
Research Article Cell biology Oncology

Druggable genome CRISPRi screen in hydrogels reveals regulators of cortactin-driven actin remodeling promoting glioblastoma invasion

  • Text
  • PDF
Abstract

To identify therapeutic targets limiting glioblastoma invasion, we applied druggable genome CRISPRi screens and multiomic analysis to patient-derived glioblastoma cells in micro-dissectible biomimetic 3D hydrogels that permitted separation and analysis of core versus invasive fractions. Of 2,550 genes screened, 12 encoded druggable targets whose suppression limited invasion, of which AURKB (encoding aurora kinase B) and ACP1 (encoding low molecular weight protein tyrosine phosphatase, LMW-PTP) were validated in neurosphere assays and in vivo. Proximity labeling identified cortactin as a link between LMW-PTP and aurora B, and we observed that cortactin underwent serine phosphorylation by aurora B and tyrosine dephosphorylation by LMW-PTP. Targeting ACP1 or AURKB via CRISPRi or inhibitors in culture and in vivo shifted the cortactin phosphorylation balance in glioblastoma, reducing levels of cortactin and the actin-related protein 2/3 (Arp2/3) complex that mediates cortactin-induced actin stabilization, thereby reducing actin-cortactin-Arp2/3 colocalization and subsequent actin polymerization. AURKB or ACP1 targeting shifted actin from cytoplasm to the nucleus, reducing mesenchymal gene expression. Biophysical analysis implicated AURKB in glioblastoma cell adhesion and stiffness needed for initial migration and ACP1 in mechanical stress resistance required for later migration. These findings revealed a targetable axis balancing kinase and phosphatase activities to regulate actin polymerization during glioblastoma invasion.

Authors

Mufeng Hu, Anna Weldy, Isabella M. Lovalvo, Erin A. Akins, Saket Jain, Alexander Chang, Ankita Sati, Meeki Lad, Austin Lui, Akhil Rajidi, Ameya Kothekar, Erika A. Ding, Juan A. Oses Prieto, Pablo Estevez, Alma L. Burlingame, Sanjay Kumar, Manish K. Aghi

×

Figure 4

Serine phosphorylation of cortactin by aurora B (AURKB) and tyrosine dephosphorylation of cortactin by LMW-PTP (ACP1).

Options: View larger image (or click on image) Download as PowerPoint
Serine phosphorylation of cortactin by aurora B (AURKB) and tyrosine dep...
(A) IP of cortactin from GBM43 cell lysates, then blotting for aurora B (upper row) and LMW-PTP (middle row) confirmed cortactin binds both proteins. Given the lower intensity of the LMW-PTP band in immune precipitate relative to aurora B, binding of LMW-PTP to cortactin was verified by precipitating LMW-PTP from the same lysates and blotting for cortactin (lower row). n = 3 technical replicates. (B) A sandwich ELISA used an anti-cortactin capture antibody and an anti-phosphorylated serine/threonine detection antibody. Incubating recombinant cortactin with aurora B and ATP revealed increased serine/threonine phosphorylation of cortactin (P < 0.05) versus reactions without aurora B. Performed with 3 technical replicates. (C) A sandwich ELISA used an anti-cortactin capture antibody and an anti-phosphorylated tyrosine detection antibody. Incubating recombinant cortactin with c-Src and ATP led to increased tyrosine phosphorylation of cortactin (P < 0.0001) versus reactions without c-Src (Supplemental Figure 4A). Incubating this tyrosine-phosphorylated cortactin with LMW-PTP decreased tyrosine phosphorylation of cortactin (P < 0.0001) versus reactions without LMW-PTP; the schematic above explains each group’s reactions. n = 3 technical replicates. Created in BioRender. (D) Targeting AURKB with CRISPRi in GBM43/sgAURKB cells or via AZD1152-HQPA revealed reduced cortactin serine phosphorylation, determined by IP of cortactin, blotting for phosphorylated serine/threonine (first row) and for cortactin (second row) or blotting the lysates without precipitation for cortactin (third row) or β-actin (fourth row). Quantification resulted from band intensities in 3 technical replicates in Supplemental Figure 4B. (E) Targeting ACP1 with CRISPRi in GBM43/sgACP1 cells or via LMW-PTP inhibitor I revealed increased cortactin tyrosine phosphorylation, determined by IP for phosphorylated tyrosine, blotting for cortactin (first row), and blotting for heavy chain antibody (second row), as well as blotting the non-precipitated lysates for cortactin (third row) and β-actin (fourth row). Quantification resulted from band intensities in 3 technical replicates in Supplemental Figure 4C. (F) Western blot for total cortactin levels confirmed CTTN knockdown in GBM43/sgCTTN cells versus GBM43/sgGAL4 control cells and revealed decreased cortactin levels in GBM43/sgAURKB cells relative to control cells, determined by quantification of band intensities in 3 technical replicates in Supplemental Figure 4D. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. One-way ANOVA with Tukey’s pairwise post hoc comparisons. Scatter dot plots show mean (horizontal bar) with SD (vertical bar).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts